Summary A series of 1,438 parents and 2,663 other relatives of retinoblastoma patients have been followed up to ascertain the incidence among them of non-ocular cancer. Among 117 of these relatives who were known carriers of the mutation of the retinoblastoma gene 23 cases of non-ocular cancer developed during the follow-up period of the study. This compares with an expected number of 2.3, a relative risk of 9.9. A total of 25 deaths among these carriers included 21 from non-ocular cancer; the expected number was 1. 8 
Retinoblastoma is a rare tumour of the retina which occurs in approximately one in 20,000 live born children. It has a strong genetic component: about 40% of all cases are associated with a heritable mutation affecting the long arm of chromosome 13 . Knudson (1978) suggested that retinoblastoma is caused by mutational events affecting homologous genes on each of a pair of chromosomes. In the hereditary form of the disease one of these mutant genes is inherited; the second mutation occurs in a somatic cell. Murphree & Benedict (1984) postulated that the 'wild type' allele Rb + at the retinoblastoma locus is a suppressor gene and controls growth: the mutant gene Rb-at this locus is recessive at the cellular level and when both genes are mutated or missing, retinoblastoma will develop.
Recent work in molecular biology has identified the particular chromosomal area containing the Rb locus; Friend et al. (1986) identified a segment of chromosome band 13q 14 which'is frequently deleted in retinoblastoma and osteosarcoma. Loss or inactivation of the retinoblastoma gene has also been reported in tumour tissue from patients with primary breast cancers (Lee et al., 1988) and small cell lung cancer (Harbour et al., 1988) , even though there is no reason to suppose that these patients had retinoblastoma.
Patients with the hereditary form of retinoblastoma who survive after treatment for the disease have a substantially increased risk of developing a second primary neoplasm, in particular an osteosarcoma (Draper et al., 1986) . The risk apparently does not affect patients with the non-hereditary form of retinoblastoma.
It has been suggested that this association of other cancers with hereditary retinoblastoma can also be manifested in a generally increased risk of cancer in the relatives of the patients (Gordon, 1974; Fedrick & Baldwin, 1978; BonaitiPellie & Briard-Guillemot, 1980; Strong et al., 1984; Tarkkanen & Karjalainen, 1984; Der Kinderen et al., 1988) . Gordon (1974) suggested that the high proportion of malignant tumours among relatives might be a consequence of other expressions of a gene causing retinoblastoma. Bonaiti-Pellie & Briard-Guillemot (1980) postulated that the excess of cancer deaths among grandparents of retinoblastoma patients could be the result of a factor of susceptibility to cancer different from the retinoblastoma gene. Strong et al. (1984) suggested that an excess of cancer deaths in relatives may be attributable to an unexpressed retinoblastoma gene or a precursor of the gene.
Materials and methods
In order to test the hypothesis that there is an increased risk of non-ocular cancer in relatives of retinoblastoma patients we have used data from two sources.
The first of these was a survey based on In the present paper we discuss the occurrence of nonocular cancers in the parents, aunts, uncles and grandparents of children with retinoblastoma. The occurrence of cancer in the siblings of retinoblastoma patients will be presented in a separate paper. Standard methods (see, for example, Coleman et al., 1986) have been used to compare cancer incidence rates and mortality from cancer and other causes in each group of relatives with that in the general population. All brain tumours and malignant neoplasms other than non-melanoma skin cancers have been included in the analysis. The observed numbers of cancers were compared with expected numbers calculated using age-sex-specific incidence rates based on data from the national cancer registration scheme for England and Wales, which is estimated to include 90% of all cancers. Expected numbers of registrations are based on data for 1968-78. Observed numbers of deaths, both from cancer and from all other causes, were compared with expected numbers calculated using age-sex-specific mortality rates for England and Wales in the appropriate 5-year calendar periods.
In calculating the observed and expected numbers of deaths among mothers we have taken the period at risk as starting at the time of birth of the child. The rationale for this is that the study group is established only at this time: deaths can only be observed after the birth of the child and expected numbers must be calculated on the same basis. The same rule was used for fathers: it might be argued that their period of risk should start at conception but provided that both expected and observed deaths are calculated from the same starting point a valid estimate of the relative risk is obtained. The same reasoning has been applied to the comparison of observed and expected numbers of cancer registrations; although it is possible that a parent may develop cancer before the birth of the index child, it seems likely that a person with cancer has a reduced chance of parenthood and thus the observed number of cancers occurring before the index children are born is likely to underestimate the true rate. Using similar reasoning the period of risk for paternal/maternal grandparents is taken to start at the date of birth of the father/mother. For aunts and uncles the period of risk is taken to start at age 1 year, since there is evidence in this study that deaths in infancy among these relatives were not fully reported. All relatives were assumed to be at risk until the effective date of follow-up defined below.
The increased incidence of, or mortality from, cancer is measured here by the ratio of observed to expected cases, which gives an estimate of the relative risk (averaged over different ages) of cancer occurring in these relatives as compared with the general population. Confidence limits for this relative risk have been calculated where appropriate by regarding the expected number of cases as a fixed quantity and the observed number as having a Poisson distribution.
Cancer in parents of retinoblastoma patients We were able to obtain sufficient identifying information about 706 fathers and 732 mothers of retinoblastoma patients in the above studies for them to be notified to the National Health Service Central Registers (NHSCR) for 'flagging'. The NHSCR routinely receives copies of all death certificates for patients and cancer registrations from 1971 onwards. As a result of this we have been informed of all deaths among the parents up to the end of 1986 and cancer registrations from 1971 to the end of 1984. (It is estimated that for 1984 more than 90% of cancers included in the national cancer registration scheme had been notified to the NHSCR by the time we analysed the results; for earlier years the proportion was much higher.) The effective date of follow-up for parents has therefore been taken as the end of 1984 for cancer registrations and the end of 1986 for deaths. For parents notified to us as having emigrated, the date at which they are lost to follow-up is taken as the date of emigration.
Parents of affected children were divided into three groups according to the likelihood that they were carriers of the mutation at the Rb locus. Known 'carriers' included those parents who had themselves had retinoblastoma or who had affected relatives in their own or a previous generation. 'Possible carriers' included parents of children with bilateral tumours and parents of more than one child with retinoblastoma. 'Probable non-carriers' consisted of parents of children with unilateral tumours and no known family history of the disease and of parents whose spouses were known carriers.
For each group the observed number of cancer registrations for all types of cancer together was compared with the expected number calculated as described above.
For the group of parents who were carriers of the retinoblastoma gene, observed and expected numbers were also compared separately for lung cancer, breast cancer, bladder cancer, brain tumours and melanoma.
In this part of the study all non-ocular cancer has been documented by cancer registrations and death certificates.
Cancer in grandparents, uncles and aunts of retinoblastoma patients Information about other relatives was obtained from the pedigree study of patients at Moorfields and St Bartholomew's Hospitals described above. This included families of 316 survivors from retinoblastoma born between 1965 and 1985. All reports of cancer among grandparents, uncles and aunts of the index child have been followed up, as have reports of deaths from causes such as pneumonia or bronchitis which might be indicative of an underlying cancer. Cancer registrations, medical records and death certificates have been obtained wherever possible for patients with cancer and those whose reported deaths came into these categories. For grandparents, medical documentation has been obtained for 81% of the reported cancers and for 86% of reported deaths from cancer. The equivalent figures for aunts and uncles are 92% and 100%.
Information about infant deaths among siblings of the interviewed parents was not complete; therefore observed and expected deaths under the age of 1 year among uncles and aunts have been excluded from the analysis.
Death certificates have not been obtained for reported deaths from specific non-cancer causes. During the interviews parents were frequently unable to give sufficiently accurate identifying information about these events.
For the analysis of reported cancers, the 'best possible' diagnosis has been used. The diagnosis was taken firstly from medical records. If these were not available, the diagnosis was taken from the cancer registration; otherwise a diagnosis based on the interview statement about cancer was used. Similarly, with deaths from all causes and deaths from cancer the diagnosis on the death certificate if available was used in the analysis; the cause of death stated in the interview was used if information given by the parent was inadequate to obtain a death certificate. The effective date of follow-up for these relatives if no cancer or death had occurred was taken to be the date of the interview or the last date each relative was known to be alive.
The relatives have been grouped according to the likelihood that they were carriers of the mutation at the Rb locus, but different criteria have been used than those for the study of the parents. For some relatives it is clear that they are carriers of the retinoblastoma gene, either because they have actually had the disease or because of the pattern of occurrence in the rest of the family (group 1, see Appendix). For the remaining relatives we have assessed the likelihood of their being carriers using criteria explained in the Appendix and illustrated in Figure 1 . For the 64 families where there is more than one case of retinoblastoma (i.e. at least one case in addition to the index child) relatives not in group 1 have been classified as group 2, with a probability of 50% of carrying the gene, or as groups 3 or 4 in order of decreasing probability. Relatives are categorised as probably not a carrier in all families where there is only one individual with retinoblastoma; this is subdivided into families where the index child had bilateral tumours (group 5), and those where the tumour was unilateral (group 6). Where there is a family history of retinoblastoma on the other side of the family, relatives are categorised as group 7.
Expected numbers of cancers and deaths were calculated using methods described above.
Results Table I gives the total numbers of relatives of retinoblastoma patients included in this study. Moorfields Eye Hospital and St Bartholomew's Hospital are centres of referral for children with retinoblastoma from other hospitals in Britain, especially for bilateral cases and those with a known family history of the disease, and thus there is a higher proportion of bilateral cases in the study of cancer in grandparents, uncles and aunts, than in the study of cancer in parents. For the possible carrier group where the index child has hereditary retinoblastoma and it is not known whether this is a new mutation or, if an inherited risk, which parent is the carrier, the risk of developing another cancer is 1.5 times that of the general population (95% confidence limits 0.9 and 2.4). For probable non-carriers there is no increased risk compared with the general population.
The low ratio (0.6) of observed to expected deaths from causes other than cancer among the probable non-carrier group of parents may be at least partly a 'healthy parent' effect (see Discussion). Table IV . For each group, with the exception of breast cancer, the observed numbers are significantly greater than the expected numbers (P<0.05 in each case).
Previous studies have suggested that there is a raised incidence of certain tumours in retinoblastoma survivors. In the younger age groups there is a particularly high risk of osteosarcomas and soft tissue sarcomas. Cancers reported in older survivors include melanoma, brain tumours and bladder cancer. Table IV shows that although the numbers of these tumours observed among carriers in the present study are small, they are greatly in excess of expectation.
In addition to the cases of cancer included in the above analysis, cancer registrations or death certificates were received for a further 22 parents. These have had to be excluded from the analysis because they did not fulfil the strict criteria for inclusion (registrations of malignant neoplasms or brain tumours after the birth of the index child, after the beginning of 1971 and before the end of 1984; and deaths before the end of 1986). In view of the association between retinoblastoma and melanoma it should be noted that in addition to the two mothers who were carriers and developed malignant melanoma and were included in the analysis, two other carrier mothers also developed malignant melanoma. One was successfully treated before the birth of the index child and the second mother developed melanoma after the end of the study date. Another tumour which has been associated with retinoblastoma is bladder cancer. One mother who was a carrier of retinoblastoma died of bladder cancer and has been included in the analysis. In addition a mother who was a possible carrier died of bladder cancer after the end of the study date, and a father included in the analysis who was said to have had a congenital cataract, but is not included among the carriers of retinoblastoma for lack of precise information, also died of bladder cancer.
Cancer in grandparents, uncles and aunts of retinoblastoma patients Three hundred and sixteen families have been included in the study of cancers in grandparents, uncles and aunts, and in 64 of these families there has been more than one case of retinoblastoma. A total of 2,663 of these relatives were identified in the course of the interviews and follow-up information obtained up to the date of the interview for nearly 99% of them. A small number of cases are excluded from the analysis because the information available for them lies outside the appropriate period of risk. of the index child, subdivded according to the likelihood of being a retinoblastoma carrier as explained in the Methods section. As with the parents of retinoblastoma patients the relatives have then been grouped into three categories: carriers, possible carriers and probable non-carriers. Ratios of observed to expected numbers are given in Table VII . The non-ocular neoplasms among relatives who are carriers of the retinoblastoma gene are listed in Table VIII . Grandparents who were carriers have a risk eight times as great as expected of developing cancer, and 11 times as great as expected of dying from cancer (the 95% confidence limits for these ratios of observed to expected numbers are 3.8 and 15.8, 5.1 and 21.2). Grandparents who were possible carriers have twice the expected risk of developing cancer and dying from cancer (95% confidence limits 1.3 and 3.0, 1.3 and 3.4). The small numbers of observed cancers and deaths from cancer among uncles and aunts who were carriers or possible carriers give wide confidence limits for the ratios, though there is a significant excess of cancer in the carrier group. The deficit of cancers observed among the relatives who are probable non-carriers may be a result of incomplete reporting of cancers and deaths or of misclassification of causes of death in cases where medical records or death certificates were not obtained.
The great majority of children in the hospital-based pedigree study were accompanied by their mothers and a comparison of the information provided about maternal and paternal relatives disclosed a generally higher reported incidence of cancers and deaths among maternal than among paternal relatives, particularly among the uncles and aunts. However, the general conclusions are unaffected by this slight bias.
There may have been a certain degree of under-reporting of events, particularly among paternal relatives, and it is possible that the excess risks are higher than quoted here. (Abramson et al., 1984; Draper et al., 1986; der Kinderen et al., 1988; Strong et al., 1984 Several studies have suggested an association between retinoblastoma and bladder cancer. Der Kinderen et al. (1988) observed two transitional cell carcinomas of the bladder among 24 carrier parents. Tarkkanen & Karialainen (1984) noted two bladder carcinomas among 19 relatives of patients with bilateral retinoblastoma. Two relatives in this study who were carriers and six other relatives of children with bilateral tumours also died of bladder cancer. Der Kinderen et al. (1988) also found three pancreatic tumours among unaffected fathers of children with hereditary retinoblastoma. In this study we noted that two unaffected parents and two unaffected grandparents of children with bilateral tumours died of cancer of the pancreas.
Among parents of retinoblastoma patients included in the cancer registration analysis there were 89 carriers of the retinoblastoma gene, of whom 70 had themselves had retinoblastoma. Non-ocular cancer developed in 20 of these survivors although the analyses of risks can only take account of 15, for reasons explained above. It is interesting that among the 19 carrier parents who had not themselves had retinoblastoma no non-ocular cancers have so far been recorded. They are known to be carriers because in addition to having a child with retinoblastoma, either siblings of their own, children of siblings or relatives in a previous generation were affected by retinoblastoma. In one family, three unaffected brothers all had children with retinoblastoma. These unaffected carriers appear to be inherently less liable to the further genetic changes which lead to the development of both retinoblastoma and subsequent non-ocular cancer. Matsunaga (1979) postulated a host resistance model whereby unaffected carriers are inherently resistant to tumour formation. However, it should be noted that among four grandparents who were certainly carriers but not reported to have had retinoblastoma themselves, three subsequently developed non-ocular cancer.
It is clear that inheritance of the Rb-gene confers susceptibility to other tumours in later life. This is shown conclusively in this study among the known carriers of the gene.
The overall excess of cancer deaths of 1.6 among relatives who were possible carriers of the retinoblastoma gene agrees with the findings of Strong et al. (1984) and can be attributed to the fact that a proportion of these relatives are also in fact carriers of the gene and have a raised likelihood of developing cancer in later life, though the risk may be less than that for carriers who are themselves affected by retinoblastoma.
When all carriers and possible carriers of the retinoblastoma gene are excluded from the analysis there is a lower than average mortality among both parents and other relatives. We think this may be partly accounted for by under-reporting of events, both deaths and cancers, and, in particular, by the implicit assumption that relatives for whom neither of these events were reported at the interview were alive and well until that time. As a consequence the relative risks reported in this paper are likely to be underestimated. An alternative explanation that may partly account for the deficit of deaths among parents is, by analogy with the 'healthy worker' effect, that members of the population who become parents are a selected group having a lower mortality than others in their age group -a 'healthy parent' effect.
